Pembrolizumab,Belzutifan,Lenvatinib,Quavonlimab,Cabozantinib,Nivolumab,Ipilimumab
merck,bms,eisai
['biomarker', 'kudos']
such a crystal clear, thoughtful approach to doublets from as front line for metastatic #kidneycancer! doublets are now established standard in trials and the need for biomarkers for future patient/tx selection. kudos for the new #care-1 trial underway in eu! #asco23 
I treat & research GU cancers @UTSW Dallas. Columbia/Harvard Med/Duke alum; Mom & wife Tweets=my opinions ASCO: https://t.co/Whk29PATXe